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Abstract
Background: Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in
solid organ transplant recipients. In addition, it is being increasingly used to treat severe or glucocorticoid-resistant
graft rejection. Despite the effectiveness of the treatment, severe adverse events have been reported related to
alemtuzumab administration. We present a similar event illustrating the severity of this adverse drug reaction (ADR)
and we highlight the structure causality assessment provides in approaching such a case.
Case presentation: We report a case of life-threatening respiratory failure after alemtuzumab administration in a
17 year old paediatric kidney transplant recipient. He developed near fatal severe respiratory and circulatory failure
based on acute respiratory distress syndrome (ARDS) with diffuse alveolar oedema and haemoptysis hours after his
second alemtuzumab administration. As it was questionable whether alemtuzumab could be regarded as the origin
of his reaction and in order to assess the causality of this reaction as well as to structure clinical reasoning, we
applied a widely used ADR probability scale to systematically review our case.
Discussion and conclusions: Our case shows a severe ADR after alemtuzumab administration. It illustrates the
importance of proper causality assessment, the structure it provides and the benefit of a clinical pharmacology
consultation when a severe reaction is suspected to be an ADR. By taking our case as an example, we demonstrate
the added value of structured causality assessment to clinical reasoning and in generating differential diagnoses.
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Background
Paediatric kidney transplantation is the treatment of
choice for patients with end-stage renal disease (ESRD).
It significantly improves survival, growth and health-
related quality of life compared to dialysis [1, 2]. In the
last decades, overall graft survival has significantly im-
proved, among others due to changes in both type of im-
munosuppressive agents and regimens [3, 4].
Alemtuzumabs mechanisms of action are CD52 antibody
dependent cellular cytolysis and complement-mediated
lysis following binding to these cells. CD52 is a peptide
of 12 amino acids, anchored to glycosylphosphatidylino-
sitol. On the cell surface of T and B lymphocytes, high
levels of CD52 peptide are present thus leading to T and
B cell depletion. Alemtuzumab is approved as a single
disease modifying therapy in adults with highly active
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relapsing remitting multiple sclerosis (MS) [5]. In solid
organ transplantation, alemtuzumab is increasingly being
used as an induction immunosuppressant agent and for
treating acute glucocorticoid-resistant rejection as alter-
native for rabbit anti-thymocyte globulin (rATG) therapy
[6]. While evidence supports similar efficacy and a better
safety profile compared to rATG, post-marketing phar-
macovigilance shows rare but serious side effects includ-
ing cardiovascular and immune-related disorders [6, 7].
We describe a 17-year old patient who developed near
fatal severe respiratory and circulatory failure based on
acute respiratory distress syndrome (ARDS) with diffuse
alveolar oedema and haemoptysis shortly after the sec-
ond alemtuzumab subcutaneous dose. Although previ-
ous case reports have described similar severe symptoms
in relation to alemtuzumab, we demonstrate the import-
ance of proper causality assessment and the benefit of a
clinical pharmacology consultation. We apply a widely
used adverse drug reaction (ADR) probability scale as
developed by Naranjo to systematically assess causality
[8]. By doing so, we demonstrate the added value of this
structured approach to clinical reasoning and in generat-
ing differential diagnoses.
Case presentation
A 17-year old boy with a history of autosomal recessive
polycystic kidney disease (ARPKD) started haemodialysis
when he was 4 years of age. At the age of 8 years, he re-
ceived a diseased donor kidney transplant. After 8 years
he lost this graft due to chronic transplant rejection and
haemodialysis needed to be restarted. Two years later, a
second kidney transplant was executed by means of a
heart beating donor. Notably, this donor had a repeated
HLA mismatch of B14. However, levels of donor specific
antibodies against B14 were not detected in his last pre-
transplant serum sample.
According to our local guideline, induction after trans-
plantation was initiated with basiliximab. Tacrolimus, my-
cophenolate mofetil and prednisolone were given as
maintenance immunosuppression therapy. Because of al-
tered graft function (creatinine 394 μmol/L and oliguria
(0.3–0.8ml/kg.h), unresponsive to furosemide), tacrolimus
was discontinued 4 days post transplantation. Day 11
post-transplant, graft function deteriorated even further
(creatinine 415 μmol/L, blood urea nitrogen 36mmol/L).
After a renal biopsy was performed, methylprednisolone
pulses were initiated and low-dose tacrolimus was
restarted. In addition, on day 12, plasmapheresis was
started for five consecutive days in order to treat a pos-
sible humoral rejection. The graft biopsy demonstrated a
type 2A acute rejection (BANFF classification: C4d posi-
tive, diffuse interstitial infiltrate, extensive oedema, focal
interstitial hemorrhage, mild tubulitis, mild acute glomer-
ulopathy and mild endovasculitis) [9]. Polyoma virus in
plasma was negative, and no viral inclusions were found
in the biopsy. Due to his underlying ARPKD, leucopenia
and thrombocytopenia were present.
Donor-specific human leukocyte antigen (HLA) anti-
bodies against B14 in plasma increased significantly.
Creatinine initially decreased from 425 μmol/L to
215 μmol/L but increased again to 376 μmol/L on day 18
(Fig. 1). Therefore, intravenous immunoglobulin G
(IVIG) was administered. Graft function improved and
tacrolimus was doubled at day 15 to a dose of 1 mg
(0.02 mg/kg).
A second graft biopsy, on day 18 post-transplant,
showed severe cellular rejection. There were minor signs
of humoral rejection as a mild influx of inflammatory
cells in the capillary lumen was observed and donor spe-
cific antibodies (DSA) against B14 mildly increased. In
order to treat this severe steroid resistant cellular rejec-
tion, with a mild humoral component in the biopsy and
mild DSA against B14, anti T-cell therapy was indicated.
A splenectomy as well as rituximab therapy were both
considered but not deemed suitable. Splenectomy to treat
antibody-mediated rejection (AMR) remains debatable as
antibodies are not solitary being produced by the spleen,
but also in lymph nodes and bone marrow. This, com-
bined with the increased risk of infection with capsuled
bacteria, argued against splenectomy. Rituximab on the
other hand, targets CD20, mainly present on memory B-
cells. However, plasma-cells responsible for antibody pro-
duction lead to CD138 expression and do not express
CD20. The leuco- and thrombocytopenia present in this
patient resulted in the choice to treat this patient with
alemtuzumab instead of rATG, as less side effects were
expected compared to other anti-T-cell therapies.
Alemtuzumab was administered subcutaneously at a
dose of 30mg. One hour prior to administration, 500mg
methylprednisone was given together with 2mg clemastin
to prevent allergic reactions and 500mg acetaminophen
to prevent development of fever and/or headaches. In
order to prevent raised levels of uric acid due to a tumour
lysis syndrome, 200mg allopurinol was given as a prophy-
laxis and hyper hydration protocol was applied (1,5–2,0 L/
m2 per 24 h). Except for a minor headache 4 h post ad-
ministration, no side effects occurred. Two days later, ta-
crolimus was discontinued due to high potassium levels
and the second dose of alemtuzumab was administered.
Seven hours after this second dose, patient complained
about a headache similar to the day before and he devel-
oped a fever up to 38.5 degrees Celsius. Within 5 h, his
clinical status deteriorated significantly. The patient be-
came dyspnoeic (oxygen saturation 87%) with 3 L of
100% oxygen and he started coughing. He was in agony,
tachypnoeic (45–50/min) with a 15 L non rebreathing
mask and his heartrate increased to 150/min with a
mean arterial pressure of 95 mmHg.
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Furosemide 80 mg was administered intravenously
without effect and the patient was transferred to the
paediatric intensive care unit (PICU) and immediately
intubated due to acute respiratory failure. He deterio-
rated within hours into severe acute respiratory distress
syndrome (ARDS) with signs of pulmonary oedema
(foamy bloody secretions). Mechanical ventilation with
maximal settings with nitric oxide (20 ppm) and abdom-
inal positioning as well as maximal inotropic treatment
with adrenalin (max 0,7 μg/kg/min), vasopressin (max 0,
04 IE/min), dobutamine (max 33 μg/kg/min) and nor-
adrenalin (max 2,1 μg/kg/min) were required. Ascites (3
L) was drained to lower ventilatory pressure before
transferring the patient into supine position. Cardiac
ultrasound showed diminished hypertrophic left ven-
tricle contractility without signs of backward failure, a
normal right ventricle and a collapsed inferior vena cava.
There were no signs of fluid overload. Fluid resuscitation
with crystalloids, packed cells and thrombocytes was ini-
tiated. Extracorporeal membrane oxygenation was not
possible due to lack of appropriate vascular access. Con-
tinuous Renal Replacement Therapy (CRRT) was started
6 h after admission to the PICU as acute kidney injury
and general oedema developed due to capillary leak syn-
drome. Yet, this failed to improve his clinical status. As
opportunistic infections as a cause for the deterioration
could not be excluded, antibiotics, ganciclovir and flu-
conazole were given. Unfortunately, the patient was too
unstable to perform a broncho-alveolar lavage for cul-
ture diagnostics. Continuing this maximal supportive
therapy, the patient stabilized after 12 h and inotropic
and vasopressive support could be tapered and ventila-
tion and oxygenation gradually improved. After 5 days
on mechanical ventilation, he was successfully extubated
and could be discharged from the PICU to the ward
after an additional 8 days. He returned home in rela-
tively good condition 33 days after his kidney transplant-
ation with a serum creatinine of 111 μmol/L.
Discussion and conclusions
This report shows a case of a severe respiratory and circu-
latory failure based on ARDS with diffuse pulmonary
oedema and haemoptysis. Uncertainty remained with
regards to the cause of this unexpected, sudden and ex-
tremely severe deterioration. With a high likelihood of an
alemtuzumab ADR, a clinical pharmacology consult was
requested and a structured approach was conducted by
using the Naranjo ADR probability score. Although
organ-specific scores exist and have a higher validity [10],
the Naranjo scale remains one of the most accessible and
therefore most frequently used ADR probability scale in
case of a single-drug-event [11]. We therefore used this
scale and demonstrate that, by applying this simple tool
and asking predefined questions, proper causality assess-
ment leads to better substantiated clinical reasoning and
might help in generating differential diagnoses. This could
therefore be considered as a first and accessible step for
any clinician encountering a possible ADR.
Naranjo et al. developed the ADR Probability Scale in
1991 in order to determine the likelihood of an ADR be-
ing actually due to administration of a drug rather than
the result of other factors [8]. By addressing the items of
the scale (Table 1), we will systematically discuss our
case and assess the probability of alemtuzumab as the
cause of the acute ARDS.
There are previous reports on similar reactions after
alemtuzumab administration (point 1). Six articles de-
scribe pulmonary reactions [12–17] including eight pa-
tients between 16 and 54 years of age. In these patients,
Fig. 1 Serum creatinine levels during clinical course in μmol/L and administered drugs. Grey area reflects admission at PICU
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alemtuzumab was prescribed for relapsing remitting MS
(n = 6) or induction after kidney transplantation (n = 2).
The severity and onset of the ADR after alemtuzumab
differed greatly between patients. All patients experi-
enced dyspnoea, fatigue and coughing, but only three
patients required ICU admission for respiratory insuffi-
ciency [15–17] of which one patient died [16]. Symp-
toms started between 24 h after the first administration
[15] to up to 2 months after the first five-day cycle [12].
In our patient, respiratory failure occurred 7 h after the
second dose and quickly worsened (point 2).
Other causes for ARDS in our patient were extensively
reviewed and were considered less likely (point 5). Fluid
overload related pulmonary oedema was rejected as ad-
ministration of diuretics nor CRRT ultrafiltration im-
proved the ARDS. Also, an infectious cause was unlikely
with an only moderately increased C-reactive protein
(CRP) (maximum of 62mg/L, 24 h after the second ad-
ministration) and blood cultures did not show any growth.
Thrombocytopenia related fatal alveolar haemorrhage was
also less likely with a thrombocyte count of 34*109/L.
Due to the severe clinical course of our patient, many
answers of the Naranjo scale will remain unanswered.
Dechallenge or changing the dose was not possible due
to the very long half-life of alemtuzumab and rechal-
lenge was obviously not tested in our patient (point
3&4). No placebo was administered and no plasma
alemtuzumab concentration was measured (point 6&7).
Our patient never experienced a similar reaction to a
different drug before (point 9).
Last, diagnosis of ARDS with diffuse alveolar oedema and
haemoptysis was supported based on bedside chest X-ray
and the clinical status of the patient (point 10). This included
chest imaging findings of new infiltrates consistent with
acute pulmonary parenchymal disease as well as the need of
mechanical ventilation with maximal support in abdominal
positioning, combined with maximal nitric oxide, inotropic
agents and CRRT. Using the paediatric ARDS criteria, this
is considered severe paediatric ARDS (PARDS) as his
respiratory failure could not be explained by cardiac fail-
ure nor by fluid overload [18].
The score of the Naranjo algorithm ranges between − 4
and 13 with 0 being a doubtful ADR and a score of 9 or
higher is considered as a definite ADR [8]. Our assessment
resulted in a score of 6 corresponding with a probable ADR.
Although severe ADRs are not excluded from the assessment
using the Naranjo probability scale, severe ADRs will have a
lower total achievable score on an individual case basis as
some items cannot be scored positive. For instance, for se-
vere ADRs, a rechallenge will often not be feasible for safety
reasons. Hence, the assessment can only result in possible or
probable causality score but will never be considered as de-
finitive (final score ≥ 9). In our case, this needs caution to in-
terpret the final score and to dismiss this as only a probable
ADR without taking the severity into account.
These shortcomings of the Naranjo scale were also ad-
dressed by García-Cortés et al. in cases of suspected hepato-
toxicity [10]. It was demonstrated that the Naranjo scale
lacks validity and reproducibility in the attribution of causal-
ity in hepatotoxicity and is considered less suitable when
organ-specific causality scales are available. However, we are
not aware of a scale specifically designed to assess causality
in case of respiratory failure and used the Naranjo scale to
demonstrate its value in structurally reviewing our case.
Many other causality assessment methods of ADRs are avail-
able, each with their own criteria for assigning causality and
an excellent overview was given by Agbabiaka et al. [11].
Some methods exclude items on rechallenge and/or the
dose-effect relation and, therefore, might be better for severe
ADR causality assessment. However, the strength of any
ADR probability scale is that it provides simple tools for sys-
tematic appraisal in assessing the causality of any ADR.
Using these tools therefore leads to a more structured clinical
reasoning that might be of help when generating differential
diagnoses. In addition, besides this assessment, we plea to be
aware of this rare but very serious ADR of alemtuzumab, es-
pecially in kidney transplant recipients where rejection is in-
creasingly being treated with this agent.
Table 1 Adverse drug reaction probability scale by Naranjo
Yes No Unknown
1. Are there previous conclusive reports on this reaction? + 1 0 0
2. Did the adverse event appear after the suspected drug was administered? + 2 −1 0
3. Did the adverse event improve when the drug was discontinued or a specific antagonist was administered? + 1 0 0
4. Did the adverse reaction reappear when the drug was readministered? + 2 −1 0
5. Are there alternative causes (other than the drug) that could on their own have caused the reaction? −1 + 2 0
6. Did the reaction reappear when a placebo was given? −1 + 1 0
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? + 1 0 0
8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? + 1 0 0
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? + 1 0 0
10. Was the adverse event confirmed by any objective evidence? + 1 0 0
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